Concert Pharmaceuticals Receives FDA Breakthrough Therapy Designation for CTP-543 for the Treatment of Alopecia Areata By: Concert Pharmaceuticals, Inc. via Business Wire News Releases July 08, 2020 at 07:00 AM EDT Related Stocks: Concert Pharmaceutic